Abstract
Mood and behavior changes are part of the clinical presentation and/or course of the dementias. The treatment of these symptoms is complex, with significant side effects and/or paucity of data limiting evidence-based guidance for the treating physician. Non-pharmacological interventions are first-line treatment for the behavior and psychological symptoms of dementia (BPSD). However, severe mood and behavioral changes often warrant pharmacological intervention requiring detailed risk/benefit analysis regarding medication choice. This chapter focuses on the clinical treatment of BPSD pertinent for the treating neurologist, providing a synopsis of the evidence supporting medication use and practical guidance on treatment selection, monitoring, and discontinuation.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Steele C, Rovner B, Chase BA, et al. Psychiatric symptoms and nursing home placement of patients with Alzheimer’s disease. Am J Psychiatr. 1990;147:1049–51.
Balestreri L, Grossberg A, Grossberg GT. Behavioral and psychological symptoms of dementia as a risk factor for nursing home placement. Int Psychogeriatr. 2000;12(Supplement 1):59–62.
Ballard CG, et al. Management of agitation and aggression associated with Alzheimer disease. Nat Rev Neurol. 2009;5(5):245–55.
Kales H, Gitlin L, Lyketsos C. Management of neuropsychiatric symptoms of dementia in clinical settings: recommendations from a multidisciplinary expert panel. J Am Geriatr Soc. 2014;62:762–9.
Kales H. Common sense: addressed to geriatric psychiatrists on the subject of behavioral and psychological symptoms of dementia. Am J Geriatr Psychiatry. 2015;23:1209–13.
Tampi RR, Tampi DJ, Balachandran S, Srinivasan S. Antipsychotic use in dementia: a systematic review of benefits and risks from meta-analyses. Ther Adv Chronic Dis. 2016;7(5):229–45.
Livingston G, Kelly L, Lewis-Holmes E, Baio G, Morris S, Patel N, Omar RZ, Katona C, Cooper C. Non-pharmacological interventions for agitation in dementia: systematic review of randomised controlled trials. Br J Psychiatry. 2014;205(6):436–42.
Cooke ML, Moyle W, Shum DH, Harrison SD, Murfield JE. A randomized controlled trial exploring the effect of music on agitated behaviours and anxiety in older people with dementia. Aging Ment Health. 2010;14:905–16.
Lin Y, Chu H, Yang CY, Chen CH, Chen SG, Chang HJ, et al. Effectiveness of group music intervention against agitated behavior in elderly persons with dementia. Int J Geriatr Psychiatry. 2011;26:670–8.
Sung HC, Lee WL, Li TL, Watson R. A group music intervention using percussion instruments with familiar music to reduce anxiety and agitation of institutionalized older adults with dementia. Int J Geriatr Psychiatry. 2012;27:621–7.
Ballard CG, O’Brien JT, Reichelt K, Perry EK. Aromatherapy as a safe and effective treatment for the management of agitation in severe dementia: the results of a double-blind, placebo-controlled trial with Melissa. J Clin Psychiatry. 2002;63:553–8.
Burns A, Perry E, Holmes C, Francis P, Morris J, Howes MJ, et al. A double-blind placebo-controlled randomized trial of Melissa officinalis oil and donepezil for the treatment of agitation in Alzheimer’s disease. Dement Geriatr Cogn Disord. 2011;31:158–64.
Zuidema S, Johansson A, Selbaek G, Murray M, Burns A, Ballard C, et al. A consensus guideline for antipsychotic drug use for dementia in care homes. Bridging the gap between scientific evidence and clinical practice. Int Psychogeriatr. 2015;27:1849–59.
FDA public health advisory: deaths with antipsychotics in elderly patients with behavioral disturbances. 2005. https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm053171.htm. Accessed 20 Feb 2017.
By the American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 updated beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2015;63(11):2227–46.
Schneider L, Pollock V, Lyness S. A meta-analysis of controlled trials of neuroleptic treatment in dementia. J Am Geriatr Soc. 1990;38:553–63.
Practice guideline for the treatment of patients with Alzheimer’s disease and other dementias. American Psychiatric Association. 2007.
Guideline watch (October 2014): practice guideline for the treatment of patients with Alzheimer’s disease and other dementias. American Psychiatric Association. 2014.
Declercq T, Petrovic M, Azermai M, Vander SR, De Sutter A, Van Driel M, et al. Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia. Cochrane Database Syst Rev. 2013;3:CD007726.
Pan Y, Wu C, Gau S, Chan H, Banerjee S. Antipsychotic discontinuation in patients with dementia: a systematic review and meta-analysis of published randomized controlled studies. Dement Geriatr Cogn Disord. 2014;37:125–40.
Reus VI, Fochtmann LJ, Evan Eyler A, Hilty DM, Horvitz-Lennon M, Jibson MD, Lopez OL, Mahoney J, Pasic J, Tan ZS, Wills CD, Rhoads R, Yager J. The American Psychiatric Association practice guideline on the use of antipsychotics to treat agitation or psychosis in patients with dementia. Am J Psychiatr. 2016;173(5):543–6.
Devanand DP, Mintzer J, Schultz SK, et al. Relapse risk after discontinuation of risperidone in Alzheimer’s disease. N Engl J Med. 2012;367(16):1497–507.
Seitz D, Adunuri N, Gill S, Gruneir A, Herrmann N, Rochon P. Antidepressants for agitation and psychosis in dementia. Cochrane Database Syst Rev. 2011;2:CD008191.
Porsteinsson AP, Drye LT, Pollock BG, Devanand DP, Frangakis C, Ismail Z, et al., CitAD Research Group. Effect of citalopram on agitation in Alzheimer’s disease – the CitAD randomized controlled trial. JAMA: J Am Med Assoc. 2014;311(7):682–91.
FDA Drug Safety Communication: revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. https://www.fda.gov/Drugs/DrugSafety/ucm297391.html. Accessed 27 Nov 2017.
Birks J. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev. 2006;(1).
McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database Syst Rev. 2006;(2).
Panza F, Solfrizzi V, Seripa D, Imbimbo B, Santamato A, Lozupone M, et al. Progresses in treating agitation: a major clinical challenge in Alzheimer’s disease. Expert Opin Pharmacother. 2015;16:2581–8.
Sadock BJ, Kaplan VA. Kaplan and Sadock’s concise textbook of clinical psychiatry. Philadelphia: Lippincott, Williams and Wilkins; 2008.
Aarsland D, Perry R, Larsen JP, et al. Neuroleptic sensitivity in Parkinson’s disease and parkinsonian dementias. J Clin Psychiatry. 2005;66(5):633–7.
Stinton C, McKeith I, Taylor JP, et al. Pharmacological management of Lewy body dementia: a systematic review and meta-analysis. Am J Psychiatry. 2015;172(8):731–42.
Lochhead JD, Nelson MA, Maguire GA. The treatment of behavioral disturbances and psychosis associated with dementia. Psychiatr Pol. 2016;50(2):311–22.
Garre-Olmo J, López-Pousa S, Vilata-Franch J, Turon-Estrada A, Hernà ndez-Ferrà ndiz M, Lozano-Gallego M, et al. Evolution of depressive symptoms in Alzheimer’s disease: one-year follow-up. Alzheimer Dis Assoc Disord. 2003;17(2):77–85.
Zubenko GS, Zubenko WN, McPherson S, Spoor E, Marin DB, Farlow MR, Sunderland T. A collaborative study of the emergence and clinical features of the major depressive syndrome of Alzheimer’s disease. Am J Psychiatr. 2003;160(5):857–66.
Lyketsos CG, Olin JT. Depression in Alzheimer’s disease: overview and treatment. Biol Psychiatry. 2002;52(3):243–52.
GarcÃa-Alberca JM. Cognitive-behavioral treatment for depressed patients with Alzheimer’s disease. An open trial. Arch Gerontol Geriatr. 2017;71:1–8.
Teri L, Logsdon RG, Uomoto J, McCurry SM. Behavioral treatment of depression in dementia patients: a controlled clinical trial. J Gerontol B Psychol Sci Soc Sci. 1997;52(4):159–66.
Teri L, Gibbons LE, McCurry SM, Logsdon RG, Buchner DM, Barlow WE, et al. Exercise plus behavioral management in patients with Alzheimer disease: a randomized controlled trial. J Am Med Assoc. 2003;290:2015–22.
Woods B, Spector A, Jones C, Orrell M, Davies S. Reminiscence therapy for dementia. Cochrane Database Syst Rev. 2005;18(2):CD001120.
Forstmeier S, Maercker A, Savaskan E, Roth T. Cognitive behavioural treatment for mild Alzheimer’s patients and their caregivers (CBTAC): study protocol for a randomized controlled trial. Trials. 2015;16:526.
Nyth AL, Gottfries CG, Lyby K, Smedegaard-Andersen L, Gylding-Sabroe J, Kristensen M, Refsum HE, Ofsti E, Eriksson S, Syversen S. A controlled multicenter clinical study of citalopram and placebo in elderly depressed patients with and without concomitant dementia. Acta Psychiatr Scand. 1992;86:138–45.
Lyketsos CG, DelCampo L, Steinberg M, Miles Q, Steele CD, Munro C, Baker AS, Sheppard JM, Frangakis C, Brandt J, Rabins PV. Treating depression in Alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS. Arch Gen Psychiatry. 2003;60:737–46.
Rabins P, Rovner BW, Rummans T, et al. Guideline watch (October 2014): practice guideline for the treatment of patients with Alzheimer’s disease and other dementias. Am J Psychiatry. 2007 Dec;164(12 Suppl):5–56.
Galynker I, Ieronimo C, Miner C, Rosenblum J, Vilkas N, Rosenthal R. Methylphenidate treatment of negative symptoms in patients with dementia. J Neuropsychiatry Clin Neurosci. 1997;9:231–9.
Rosenberg PB, Lanctôt KL, Drye LT, Herrmann N, Scherer RW, Bachman DL, Mintzer JE. ADMET Investigators: safety and efficacy of methylphenidate for apathy in Alzheimer’s disease: a randomized, placebo-controlled trial. J Clin Psychiatry. 2013;74(8):810–6.
Frakey LL, Salloway S, Buelow M, Malloy P. A randomized, double-blind, placebo-controlled trial of modafinil for the treatment of apathy in individuals with mild-to-moderate Alzheimer’s disease. J Clin Psychiatry. 2012;73(6):796–801.
Tew JD Jr, Mulsant BH, Haskett RF, Prudic J, Thase ME, Crowe RR, Dolata D, Begley AE, Reynolds CF III, Sackeim HA. Acute efficacy of ECT in the treatment of major depression in the old-old. Am J Psychiatry. 1999;156:1865–70.
Rao V, Lyketsos CG. The benefits and risks of ECT for patients with primary dementia who also suffer from depression. Int J Geriatr Psychiatry. 2000;15:729–35.
O’Connor MK, Knapp R, Husain M, Rummans TA, Petrides G, Smith G, Mueller M, Snyder K, Bernstein H, Rush AJ, Fink M, Kellner C. The influence of age on the response of major depression to electroconvulsive therapy: a C.O.R.E. report. Am J Geriatr Psychiatry. 2001;9:382–90.
Thapa PB, Gideon P, Cost TW, Milam AB, Ray WA. Antidepressants and the risk of falls among nursing home residents. N Engl J Med. 1998;339:875–82.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Newman, B.M. (2018). Treating the Behavioral Symptoms of Dementia. In: Grossberg, G., Kinsella, L. (eds) Clinical Psychopharmacology for Neurologists. Springer, Cham. https://doi.org/10.1007/978-3-319-74604-3_7
Download citation
DOI: https://doi.org/10.1007/978-3-319-74604-3_7
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-74602-9
Online ISBN: 978-3-319-74604-3
eBook Packages: MedicineMedicine (R0)